CSL's $3.1 billion bid for Talecris challenged by US regulator - updated
This article was originally published in Scrip
Executive Summary
The US Federal Trade Commission (FTC) is to file a complaint in the US Federal District Court challenging CSL's proposed acquisition of Talecris Biotherapeutics for $3.1 billion. The regulator says that the deal would reduce competition in the US for four plasma-derived therapies.